How I manage donors and patients with a weak D phenotype

Curr Opin Hematol. 2006 Nov;13(6):476-83. doi: 10.1097/01.moh.0000245694.70135.c3.

Abstract

Purpose of review: Since the adoption of molecular blood-group typing, the considerable heterogeneity of the serologic entities weak D and DEL at the molecular level has come to light. I offer an approach to the management of donors and patients expressing D antigen weakly and carrying any of the various molecular types of weak D and DEL.

Recent findings: More than 50 distinct weak D alleles have been described. An internet-based survey of anti-D immunizations occurring in D-positive transfusion recipients reveals that no allo-anti-D has been observed in patients carrying prevalent weak D types. Allo-immunizations are documented for weak D types 4.2 (also known as DAR), 11 and 15. Anti-D immunizations have been reported in D-negative persons transfused with weak D and DEL red blood cells.

Summary: Patients carrying any of the prevalent weak D types 1, 2, 3 or 4.1 are not prone to allo-anti-D immunization and may safely be transfused with D-positive red blood cells. Pregnant women with these weak D types need not receive RhIg. We should pay attention to weak D- or DEL-positive blood units that are labelled D-negative. The clinical benefit of removing DEL blood units from our supply of D-negative red blood cell units should be determined.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution / genetics
  • Blood Donors*
  • Blood Grouping and Crossmatching / methods*
  • Chimera
  • Humans
  • Molecular Diagnostic Techniques / methods*
  • Rh-Hr Blood-Group System / analysis*
  • Rh-Hr Blood-Group System / blood
  • Rh-Hr Blood-Group System / genetics
  • Sensitivity and Specificity

Substances

  • Rh-Hr Blood-Group System
  • Rho(D) antigen